Enveric Biosciences, Inc. (NASDAQ:ENVB) to Post Q1 2025 Earnings of ($0.40) Per Share, Diamond Equity Forecasts

Enveric Biosciences, Inc. (NASDAQ:ENVBFree Report) – Analysts at Diamond Equity issued their Q1 2025 earnings estimates for shares of Enveric Biosciences in a research note issued to investors on Monday, April 1st. Diamond Equity analyst H. Diamond forecasts that the company will post earnings per share of ($0.40) for the quarter. The consensus estimate for Enveric Biosciences’ current full-year earnings is ($2.65) per share. Diamond Equity also issued estimates for Enveric Biosciences’ Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.35) EPS and Q4 2025 earnings at ($0.31) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Enveric Biosciences in a report on Tuesday, January 30th.

Get Our Latest Analysis on Enveric Biosciences

Enveric Biosciences Stock Down 11.4 %

ENVB opened at $1.01 on Thursday. The company has a 50 day moving average of $1.03 and a 200 day moving average of $1.44. Enveric Biosciences has a 12 month low of $0.65 and a 12 month high of $6.98.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Armistice Capital LLC bought a new position in Enveric Biosciences in the 4th quarter valued at $355,000. AdvisorShares Investments LLC boosted its holdings in Enveric Biosciences by 46.2% in the 3rd quarter. AdvisorShares Investments LLC now owns 146,833 shares of the company’s stock valued at $339,000 after purchasing an additional 46,404 shares during the period. Citadel Advisors LLC bought a new position in Enveric Biosciences in the 2nd quarter valued at $47,000. Renaissance Technologies LLC bought a new position in Enveric Biosciences in the 2nd quarter valued at $58,000. Finally, Millennium Management LLC bought a new position in Enveric Biosciences in the 2nd quarter valued at $49,000. 13.82% of the stock is owned by institutional investors.

Enveric Biosciences Company Profile

(Get Free Report)

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis.

Read More

Earnings History and Estimates for Enveric Biosciences (NASDAQ:ENVB)

Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.